TG Therapeutics Inc (NASDAQ:TGTX) Forecasted to Post FY2020 Earnings of ($1.71) Per Share

TG Therapeutics Inc (NASDAQ:TGTX) – Analysts at SunTrust Banks cut their FY2020 EPS estimates for shares of TG Therapeutics in a research report issued on Monday, April 1st, Zacks Investment Research reports. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.69). SunTrust Banks also issued estimates for TG Therapeutics’ FY2021 earnings at ($1.59) EPS and FY2022 earnings at ($0.40) EPS.

Other analysts have also issued research reports about the company. BidaskClub raised TG Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. B. Riley started coverage on TG Therapeutics in a report on Tuesday, January 8th. They issued a “buy” rating and a $10.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Tuesday, January 22nd. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Wednesday, February 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of TG Therapeutics in a report on Wednesday, February 6th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $14.07.

Shares of TGTX stock traded down $0.09 during trading on Thursday, reaching $8.00. The company had a trading volume of 1,139,376 shares, compared to its average volume of 2,148,954. The company has a market capitalization of $711.69 million, a price-to-earnings ratio of -4.19 and a beta of 2.31. TG Therapeutics has a one year low of $3.32 and a one year high of $16.00.

Several large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of TG Therapeutics by 239.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,117 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 9,255 shares in the last quarter. Baldwin Brothers Inc. MA grew its holdings in shares of TG Therapeutics by 67.2% during the 1st quarter. Baldwin Brothers Inc. MA now owns 29,850 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 12,000 shares in the last quarter. Mycio Wealth Partners LLC grew its holdings in shares of TG Therapeutics by 56.3% during the 1st quarter. Mycio Wealth Partners LLC now owns 70,350 shares of the biopharmaceutical company’s stock worth $566,000 after purchasing an additional 25,350 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of TG Therapeutics by 72.2% during the 4th quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock worth $3,378,000 after purchasing an additional 345,477 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of TG Therapeutics by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 755,205 shares of the biopharmaceutical company’s stock worth $3,096,000 after purchasing an additional 70,398 shares in the last quarter. 55.53% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Story: What does cost of debt say about a company’s financial health?

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.